Visual Abstract

Purpose: To evaluate the association between the eGFR trajectory and cardiovascular/renal outcomes in SGLT2i users.

Methods: Cardiovascular and Renal Outcome Trials of SGLT2i with reports of eGFR change were included. Random-effect model was used.

Results: In all, 7 RCTs were included. Meta-analysis showed that the risk of all-cause mortality was only reduced in SGLT2i users with eGFR change rate >-1ml/min/1.73m2 per year (RR=0.87, 95%CI, 0.77 to 0.99). Consistent risk reductions were observed in SGLT2i users in terms of heart failure, 3P-MACE (MI, stroke, CV death), 4P-MACE (3P-MACE and heart failure) and composite renal endpoints (sustained decline in eGFR, renal replacement treatment and renal death), regardless of eGFR change rate.

Conclusions: The preserved eGFR decline may confer reduced risk of all-cause mortality but did not influence the benefits in cardiovascular and renal outcomes in SGLT2i users.

graphic
View largeDownload slide
Disclosure

C. Lin: None. X. Cai: None. L. Ji: None.

Funding

Beijing Natural Science Foundation (7202216); National Natural Science Foundation of China (81970698, 81970708)

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.